Conclusions and options for response

Since February 2016, 287 confirmed hepatitis A cases infected with three distinct strains of sub-genotype IA virus have been reported by 13 EU countries. These include cases from eight additional countries, 263 more cases and one additional strain compared with the data reported in the first risk assessment published on the 19 December 2016. Most cases are reported among adult men who have sex with men (MSM), with only nine women affected.

The main prevention measure in the context of the current outbreaks is hepatitis A vaccination of MSM. The ECDC guidance for HIV and sexually transmitted infection (STI) prevention among men who have sex with men encourages Member States to offer and promote vaccination of MSM against hepatitis A [1]. Information on vaccine availability should be included in health promotion programmes targeting MSM, particularly at sex venues [2].

Where hepatitis A vaccination is not universally offered to MSM or uptake is low, the following groups could be prioritised for vaccination:

- MSM travelling to destinations reporting outbreaks of hepatitis A among MSM;
- MSM living in areas of ongoing outbreaks;
- MSM at risk of severe outcomes from hepatitis A infection, for example those with hepatitis B virus and/or hepatitis C virus infection and those who inject drugs.

In addition to vaccination, the following options should be considered for preventing transmission among MSM:

- Provide primary prevention advice and promote vaccination by engaging with civil society, social media, the gay press and gay-dating apps;
- Increase awareness among healthcare providers about ongoing outbreaks of hepatitis A virus (HAV) infection among MSM and promote vaccination in health clinics;
- Emphasise the importance of partner notification with healthcare providers;
- Provide post-exposure prophylaxis to identified sexual contacts, household contacts and other relevant close contacts of cases through the hepatitis A vaccine and human normal immune globulin according to national guidelines in order to prevent secondary cases;
- Raise awareness among MSM on the risk of contracting hepatitis A through risky sexual behaviour;
- Educational efforts targeting MSM at high risk should emphasise the importance of HAV vaccination and of personal hygiene (e.g. washing hands and genital areas before and after sex). The use of dental dams for oral-anal sex may offer protection against hepatitis A and of condoms for anal sex against other STIs.
- All hepatitis A cases among MSM should be referred to sexual health services for further STI/HIV testing;

© European Centre for Disease Prevention and Control, Stockholm, 2017
Hepatitis A cases should be notified to public health authorities and where required, temporarily excluded from work according to national legislation and guidance.

Sharing of microbiological and epidemiological details of new cases and questionnaires used during outbreak investigations through the Epidemic Intelligence Information System for Food- and Waterborne Diseases and Zoonoses (EPIS-FWD) is encouraged for monitoring the epidemiological situation.

Source and date of request

Public health issue
Ongoing transmission of hepatitis A virus (HAV) infection mainly affecting men who have sex with men (MSM) in EU/EEA countries.

Consulted experts
ECDC internal response team in alphabetical order: Erika Duffell, Anke Kohlenberg, Katrin Leitmeyer, Otilia Mardh, Taina Niskanen, Ettore Severi, Gianfranco Spiteri, Lara Payne-Hallstrom, Therese Westrell.

External experts consulted: Stephan Aberle (Medical University of Vienna, Austria), Franz Allerberger (Austrian Agency for Health and Food Safety, Austria), Ana Avellon Calvo (Viral Hepatitis Reference and Research Laboratory, Carlos III Health Institute, Spain), Kazim Beebeejaun (Public Health England, UK), Koye Balogun (Public Health England, UK), Roberto Bruni (Istituto Superiore di Sanita, Italy), Anna Rita Ciccaglione (Istituto Superiore di Sanita, Italy), Michael Edelstein (Public Health England, UK), Josefine Ederth (Public Health Agency of Sweden), Mirko Faber (Robert Koch Institute, Germany), Sofieke Klamr (Scientifique Institute of Public Health, Belgium), Virginie Maes (Scientifique Institute of Public Health, Belgium), Sofie Elisabeth Midgley (Statens Serum Institut, Denmark), Luise Mueller (Statens Serum Institut, Denmark), Siew Lin Ngui (Public Health England, UK), Sophie Quoilin (Scientifique Institute of Public Health, Belgium), Lena Sundqvist (Public Health Agency of Sweden), Rita de Sousa (National Institute of Health Doutor Ricardo Jorge, Portugal), Caterina Rizzo (Istituto Superiore di Sanita, Italy), Leila Thornton (HSE Health Protection Centre, Ireland), Maria Elena Tosti (Istituto Superiore di Sanita, Italy), Carmen Varela Martin (Carlos III Health Institute, Spain), Harry Vennema (National Institute for Public Health and the Environment, the Netherlands), Jürgen Wenzel (National Consultant Laboratory for HAV and HEV, Germany), Dirk Werber (State Office for Health and Social Affairs, Berlin, Germany).

Disease background information
Hepatitis A is an acute, usually self-limiting infection caused by the hepatitis A virus. Transmission is predominately by the faecal-oral route, through contaminated water or food-products and/or by person-to-person contact. Transmission through sexual exposure has been associated with outbreaks in men who have sex with men (MSM), and transmission through sharing of needles and syringes with outbreaks among people who inject drugs. Parenteral transmission through infected instruments or, rarely, blood components has been documented [3].

The infection is asymptomatic or mild in children, but both the proportion of symptomatic infections and the severity of the presentation increases with age. Adults may develop jaundice and present with more severe clinical symptoms. The case-fatality ratio is generally 0.1%, but can be 1.8% in adults >50 years of age and in immunocompromised patients. The mean incubation period is 28 days, ranging from 15 to 50 days. The maximum infectivity is in the second half of the incubation period (i.e. while asymptomatic) and most cases are considered non-infectious after the first week of jaundice. The diagnosis is made by serology or molecular tests. Anti-HAV IgM serology and detection of HAV-RNA indicate acute infection. Almost all human hepatitis A viruses belong to genotypes I and III, with genotype I being divided into sub-genotypes IA and IB. Genotype I is the most prevalent, comprising at least 80% of circulating human strains [4,5].

No specific treatment is available for hepatitis A infection. Strict control measures such as enforcing personal hygiene, contact tracing and administration of the vaccine to exposed persons have been shown to be effective in reducing transmission. Active and passive immunisation is effective if administered within two weeks of exposure. Several inactivated vaccines are available for prevention [6]. Post-exposure prophylaxis should be administered according to national guidelines.
In 2015, 12,527 confirmed hepatitis A cases were reported to the European Surveillance System (TESSy) by 30 EU/EEA countries. Romania accounted for 41% of the cases and Bulgaria for 9%. Cases were reported among all age groups with most cases among 5–14 year-olds (39%) and 25–44 year-olds (19%). Male cases were more frequent than female ones, particularly in age groups 15–24 and 25–44 years, with a male to female (M:F) ratio of 1.3 and 1.2, respectively. The majority (91%) of infections were acquired in the country of residence. However, the percentage of travel-associated cases varied from zero to 100% across Europe. Syria, Morocco and Turkey were the most common travel destinations among travel-associated cases. Among the 479 cases related to travel within the EU/EEA for the period 2010–2015, the male-to-female ratio was 1.4.

Hepatitis A seroprevalence presents a high degree of temporal and spatial variability across the EU/EEA, with increasing seroprevalence from northern to central, southern and eastern EU/EEA. The susceptibility to infection among adults is highest in northern EU/EEA countries and lowest in eastern EU countries. There is an overall decreasing trend of the seroprevalence over the last four decades [3].

Outbreaks of hepatitis A among MSM have been recognised since the 1970s [7-10]. Several multinational outbreaks have been described, one of which involved at least eight cities across three countries and two continents, North America and Australia, and occurred from January through June 1991 [11]. Several European countries reported national outbreaks in MSM in the past decades. The main risk factor is related to direct oral-anal contact during sex [12-15]. The current level of immunity among the MSM population in Europe is unknown. It has been estimated that a level of >70% immunity among the MSM population would prevent sustained transmission and future outbreaks [16].

### Event background information

#### Descriptive epidemiology

Since the publication of the first RRA on hepatitis A among MSM on 19 December 2016, two additional urgent inquiries were launched in EPIS FWD, by Germany on 11 January 2017 and by the Netherlands on 31 January 2017. The investigations of these events have identified three separate clusters based on genetic sequencing of the hepatitis A virus (HAV) (Figure 1). The descriptive epidemiology is presented for each cluster as they probably indicate separate transmission chains.

**Figure 1.** Distribution of hepatitis A cases by month of report and genetic sequence, June 2016–February 2017, EU/EEA (n=179).

Note: 108 cases with missing date of report are not included.

**Event 1 – Cluster VRD_521_2016**

On 6 December 2016, through an EPIS FWD urgent inquiry, the United Kingdom (UK) reported 15 hepatitis A cases with onset of symptoms between July and November 2016, infected with an identical viral RNA sequence of genotype IA, geographically grouped in three clusters in England and one case in Northern Ireland. All cases are male and most (12/15) identify as MSM. Five cases reported travel to Spain.
As of 22 February 2017, ten EU Member States have reported 190 cases with an identical virus sequence: Spain (70, preliminary data), Italy (41), the United Kingdom (30), Germany (17), France (14), Portugal (9), Finland (3), Ireland (3), the Netherlands (2) and Sweden (1). Seventy-seven (94%) of 82 documented cases are male and 33 of 41 documented cases identify themselves as MSM. The median age of cases is 30.5 years, ranging from 18 to 63 years. Seventeen of the 62 cases with information provided are travel-associated of whom 11 cases travelled to Spain and two had visited Spain in addition to one or more countries during a trip.

**Figure 2. Distribution of cases associated with cluster VRD_521_2016 by reporting country and month (n=87), June 2016-February 2017, EU/EEA.**

![Graph showing distribution of cases](image)

Note: Thirty-two cases from Italy and 70 cases from Spain with missing month of report are not included. One travel-related female case reported by Sweden in March 2016 is not included.

On 21 February 2017, Portugal notified 23 cases diagnosed since December 2016 (week 52) through the Early Warning and Response System, of which nine have the sequence VDR_521_2016 (14 cases are still under investigation). The 23 cases are males, 31 years of age on average and 10 are MSM. An increase in the number of HAV cases has been observed in Portugal in recent years, with 26 cases reported in 2015, 55 cases in 2016 (provisional data) and 48 cases in 2017 as of 21 February, of whom 94% are men (provisional data).

**Event 2 – Cluster RIVM-HAV16-090**

On 14 October 2016, the Netherlands notified two cases of hepatitis A among MSM who participated in the EuroPride festival in Amsterdam between 23 July and 7 August 2016 through the Early Warning and Response System. The cases were infected with an indistinguishable IA genotype sequence, but different from the VRD_521_2016 cluster. The two individuals visited the same location on 2–3 August 2016 where they reported engaging in anonymous sexual activities. They developed symptoms on 11 and 15 September 2016, respectively. The clustering in time and place of the cases, along with an identical viral sequence suggest a person-to-person transmission through the sexual route, but cannot exclude food or waterborne transmission.

As of 22 February 2017, nine EU Member States have reported 70 cases with an identical virus sequence: 31 cases in the United Kingdom, ten in the Netherlands, eight in Germany, five in Austria, five in Belgium, five in France, three in Sweden, two in Italy and one in Spain. Sixty-six of 67 documented cases are male and 44 of 49 documented cases identify themselves as MSM. The median age of cases is 36 years, ranging from 25 to 83 years. Twenty-four of 61 cases with information provided are travel-associated of which 14 cases reported travelling to Spain.
Hepatitis A outbreaks in EU/EEA mostly affecting MSM, 23 February 2017

Figure 3. Distribution of cases associated with cluster RIVM-HAV16-090 by reporting country and month (n=67), June 2016–February 2017, EU/EEA.

Note: Only 5/19 cases with available genotyping information are represented for Belgium in this figure. Two cases from Italy and one case from Spain missing date of report are not included.

On 20 February, Belgium notified 19 cases of hepatitis A diagnosed since December 2016 through the Early Warning and Response System among MSM. In addition, several cases occurred in non-MSM (according to the treating physician) and without a known source. Five of the samples from MSM were typed, and matched the strain circulating in the Netherlands and linked to the EuroPride-Amsterdam 2016.

Event 3 – Cluster V16-25801

On 11 January 2017, through an EPIS FWD urgent inquiry, Germany notified three clusters of hepatitis A, predominantly males, reported in Berlin in November and December 2016. Cases were related to the two clusters described above, but a new cluster was also described that included cases in Munich and Frankfurt since August 2016. The distinct genotype IA was denoted V16-25801.

As of 22 February 2017, seven EU Member States have reported 27 cases with identical virus sequence: 18 cases in Germany, three in the United Kingdom, two in Italy and one case each in Austria, Denmark, the Netherlands and Spain. Nineteen of 20 documented cases are male and five identify themselves as MSM. The median age of cases is 30 years, ranging from 24 to 51 years. Four of 14 cases with information provided, are travel-associated and two of the four had travelled to Germany.
Figure 4. Distribution of cases associated with cluster Cluster V16-25801 by reporting country and month (n=25), June 2016–February 2017, EU/EEA.

Note: One case reported by Italy and one reported by Spain with missing date of report are not included in the figure.

Additional information from national outbreak investigations

Two recent publications on the ongoing outbreaks involving multiple strains in the UK [17] and Germany (Berlin) [18] complement the information reported in EPIS FWD platform as described above. They report findings from national outbreak investigations and further describe characteristics of the cases and identify potential drivers of the outbreaks. The following characteristics were identified among the UK cases: co-infections with sexually transmitted infections, multiple partners, sex-work, use of sex-on-site premises (saunas, clubs) and dating apps (Grindr, Recon). Further spread among household contacts of two MSM cases was reported.

Germany has reported 38 cases as of 20 January 2017. Twenty-six of 27 documented cases were unvaccinated or incompletely vaccinated, 30 of 32 documented cases identified themselves as MSM, one male as heterosexual and the only female case as having sex with other women. While six cases were potentially infected abroad, the majority were apparently infected in Germany, probably in Berlin. The risks of spread of HAV strains across Europe due to the nationally and internationally well-connected MSM scene in Berlin was highlighted in the publication [18].

Microbiological investigation

Cluster VRD_521_2016

The HAV strain VRD_521_2016 of sub-genotype IA is characterised by an identical viral RNA sequence of 505 nucleotides from the VP1/2A region. The UK shared this sequence with the European FWD network and ECDC informed the STI contact points through EPIS STI. The strain is phylogenetically related to strains derived from Central/South America, based on analysis of European databases (HAVNET).

Cluster RIVM-HAV16-090

The sequence of HAV strain RIVM-HAV16-090 sub-genotype IA was shared in EPIS FWD and EPIS STI with the respective networks. The sequence is a 460 nucleotides long fragment from the region VP1/2A according to HAVNet protocol [19]. The sequence is closely related to strains reported by Japan and China, so most probably originally from Asia. In 2015, the UK detected this sequence in a traveller returning from Hong Kong, China. Recently, the strain was found to be identical to the strain involved in the ongoing outbreak among MSM in Taiwan.

The sequence of RIVM-HAV16-090 is only 95.4% similar to the VRD_521_2016, suggesting unrelated transmission events.
Cluster V16-25801

The sequence of HAV strain V16-25801 sub-genotype IA was shared in EPIS FWD and EPIS STI by Germany. The sequence is a 459 nucleotides long fragment from the region VP1/2A according to HAV-Net protocol [19]. The sequence of V16-25801 is only 96.1% similar to the VRD_521_2016 and 96.5% similar to the RIVM-HAV16-090, suggesting unrelated transmission events.

ECDC threat assessment for the EU

Between February 2016 and February 2017, 13 EU countries have reported three clusters involving 287 HAV confirmed cases, associated with three different HAV sequences of genotype IA. Each of these clusters involve between seven and ten different EU Member States. The extent of these outbreaks is likely to be underestimated, as reported cases are limited to those attending healthcare facilities and for which sequencing was performed.

Most cases are reported among HAV-unvaccinated adult MSM, with only a few women affected. No cases of infected food handlers have been reported associated to these events, nor has there been any indication of associated foodborne transmission. Thus, these clusters are considered mainly propagated by person-to-person sexual transmission. However, the several reports of household transmission linked to these clusters highlight the need for early contact tracing and post-exposure prophylaxis to close contacts, in order to avoid infections among unvaccinated household contacts.

Scientific articles on these clusters published after the ECDC rapid risk assessment of 19 December 2016 further indicate unvaccinated MSM as the European population group most at risk of being affected by these clusters, and provide further insight into the high-risk sexual practices associated with HAV transmission. In particular, they indicate anonymous sex, multiple sex partners, sex-on-premises venues and use of dating apps as factors associated with these outbreaks.

The multinational dimension of these clusters may be explained by the highly interconnected sexual networks among MSM in Europe. In at least two EU Member States, the United Kingdom and Germany, secondary cases have been linked to travel-associated index cases. The circulation of three different HAV genotype IA strains in the MSM population is likely to be the result of several introductions into these networks.

Further transmission resulting from these clusters may be prevented by vaccination of MSM and post-exposure prophylaxis in identified contacts. However, limited vaccine availability in some countries may have an impact on the implementation of such control measures.
References